Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/24993
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBelhassen, Manon
dc.contributor.authorNibber, Anjan
dc.contributor.authorVan Ganse, Eric
dc.contributor.authorRyan, Dermot
dc.contributor.authorLanglois, Carole
dc.contributor.authorAppiagyei, Francis
dc.contributor.authorSkinner, Derek
dc.contributor.authorLaforest, Laurent
dc.contributor.authorSoriano, Joan B
dc.contributor.authorPrice, David
dc.date.accessioned2019-06-28T14:24:37Z-
dc.date.available2019-06-28T14:24:37Z-
dc.date.issued2016
dc.identifier.citationNPJ Prim Care Respir Med.2016 10;(26):16076
dc.identifier.urihttps://hdl.handle.net/20.500.12530/24993-
dc.description.abstractAgainst recurrent controversies around the safety of short- and long-acting β2-agonists (SABA and LABA), and the National Review of Asthma Deaths inquiry in the United Kingdom, we investigated the prevalence of inappropriate therapy in asthma. Our study aimed to determine the prevalence of inappropriate use of asthma therapy in the United Kingdom and in France. Two interval, parallel, population-based cohorts (2007 and 2013) were developed in each country by using the UK OPCRD and the French EGB databases. Patients aged 6-40 years were studied over the 12-month period following inclusion, regarding overuse (⩾12 units) of SABA, use of LABA without inhaled corticosteroids (ICS) and ⩾2-fold higher use of LABA compared with that of ICS. Overall, 39,743 UK and 4,910 French patients were included in 2007, and 14,036 and 5,657 patients, respectively, were included in 2013. UK adults were more frequently exposed to SABA overuse compared with those in France in both periods, with an upward trend in the United Kingdom (P<0.05). In 2013, LABA use without ICS occurred in 0.1% and 1.5% of United Kingdom and French adults, respectively. Unbalanced use of LABA relative to ICS became marginal in both countries in 2013. Inappropriate use of therapy was less marked, but present, in children. Inappropriate therapy remains a common issue in asthma. Based on our figures, it may be estimated that >210,000 British and >190,000 French asthmatics aged 6-40 years were inappropriately treated in 2013.
dc.language.isoeng
dc.rightsopenAccess-
dc.subject.meshAdministration, Inhalation
dc.subject.meshAdolescent
dc.subject.meshAdrenal Cortex Hormones
dc.subject.meshAdrenergic beta-2 Receptor Agonists
dc.subject.meshAdult
dc.subject.meshAsthma
dc.subject.meshChild
dc.subject.meshCohort Studies
dc.subject.meshDatabases, Factual
dc.subject.meshDrug Therapy, Combination
dc.subject.meshFemale
dc.subject.meshFrance
dc.subject.meshHumans
dc.subject.meshInappropriate Prescribing
dc.subject.meshMale
dc.subject.meshPractice Patterns, Physicians'
dc.subject.meshUnited Kingdom
dc.subject.meshYoung Adult
dc.titleInappropriate asthma therapy-a tale of two countries: a parallel population-based cohort study.
dc.typeArtículo
dc.identifier.pubmedID27735927
dc.format.volume26
dc.format.page16076
dc.identifier.e-issn2055-1010
dc.identifier.journalNPJ primary care respiratory medicine
dc.identifier.doi10.1038/npjpcrm.2016.76
dc.identifier.pmcPMC5063035
dc.pubmedtypeJournal Article
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. La Princesa > Artículos

Files in This Item:
File Description SizeFormat 
PMC5063035.pdf453.94 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.